ORIC Pharmaceuticals, Inc. (ORIC)

NASDAQ • Healthcare

$12.04

-$0.03 (-0.2%)

Market closed

Last close at September 11, 2026 at 20:00 UTC

Open$12.26

Day Range$12 - $12.41

Avg. Volume (3M)1M

Market Cap$1.2B

52 Week Range

$7.23$14.93

Next EarningsIn 60 daysNov 12, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$140.3M

EPS (TTM)

-$1.35

ROA (TTM)

-34.68%

Current Ratio

13.19

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-2.2%Q3 2025-$0.47

+19.5%Q4 2025-$0.33

+11.8%Q1 2026-$0.3

-6.0%Q2 2026-$0.34

-5.7%Q3 2026-$0.38

Nov 12

in 60 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -5.7%

ORIC Pharmaceuticals’ earnings trailed consensus as EPS came in at -$0.38 versus the -$0.36 estimate (difference -$0.02), based on preliminary results for the second fiscal quarter of 2026 that were reported on August 3, 2026. The company posted a GAAP net loss of about $41.5 million, down ~14% from a net loss of roughly $36.4 million a year ago, alongside GAAP operating income of around -$45.3 million as the early-stage oncology pipeline (including ORIC-533, ORIC-944, and ORIC-114) continued to drive operating spending. Cash flow from operations was negative at about $31.6 million, and the company repurchased roughly $1.3 million of stock during the quarter. For the next period, consensus calls for EPS of -$0.40.

View full earnings history

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. is a NASDAQ-listed Biotechnology company developing treatments for cancer patients in the United States. Founded in 2014 and based in South San Francisco, California, ORIC operates as an early-stage drug developer focused on precision medicines aimed at cancer resistance, and it has traded publicly since its 2020 IPO.

Name

ORIC Pharmaceuticals, Inc.

CEO

Jacob Chacko

Website

www.oricpharma.com

Industry

Healthcare

Year Founded

2014

Employees

111

Today's Snapshot

AI-generated

The day ended with ORIC slightly lower at 12.04, in line with a flat sector.

Trading Volume

Below 10d avg (1.1M)

vs S&P 500 Today

Underperforming Market

-1.18%

Updated: September 11, 2026 at 20:27 UTC

Technical Indicators

3 Buy1 Neutral4 Sell

ORIC shows clear near‑term weakness despite remaining above long‑term averages: the stock is trading around 12.04 while short and medium moving averages sit above the price, and momentum indicators including CCI and MACD are negative. Trend strength is modest with ADX in the mid‑20s, and volume pressure is negative as OBV remains depressed. Volatility is elevated relative to the share price with an ATR near 0.67, and the classic pivot at 12.29 is holding. Technical takeaway: Sell.

All signals